ERBB2 and breast cancer: Similarly, Liu et al. employed single-cell methodologies in HER2+ breast cancer xenografts to monitor the development of treatment-resistant clones, demonstrating that these cells entered a quiescent, slow-cycling state capable of subsequently inducing relapse (Liu et al., 2025).